admin – Page 5762 – Get News Story

St. Paul’s Senior Services Participates in San Diego Pride Festival

San Diego, Calif. – Aug 5, 2024 – St. Paul’s Senior Services (SPSS) proudly participated in the 2024 San Diego Pride Parade and Festival, a two-day event in Balboa Park, to demonstrate its support for LGBTQIA+ individuals and seniors in the community. The organization’s inaugural appearance reinforced its mission of transforming the aging experience and improving the quality of life for those it serves.

St. Paul’s employees embraced the slogan “Standing Proud with Pride” at two festival booths offering information on St. Paul’s programs, services, and communities. Special emphasis was placed on The Manor on Bankers Hill, a newly-renovated retirement community for active seniors that welcomes LGBTQIA+ individuals and couples over 55.

“Everyone has a place at our table here—especially the underserved, overlooked, and most vulnerable in our community,” said Craig Smith, Director of Donor Engagement for the St. Paul’s Senior Services Foundation. “I was honored to represent St. Paul’s at PRIDE this year and especially proud to share our mission of serving seniors with the LGBTQ+ community and their allies.”

St. Paul’s Senior Services’ participation in the parade was made possible through a collaboration with San Diego Oasis. Both organizations were located in the festival’s Senior Cool Zones, which provided shade and critical resources to seniors throughout the weekend.

St. Paul’s Senior Services is currently hiring for several positions across various departments. Individuals who are passionate about making a difference in the lives of seniors are encouraged to apply. For more information about available opportunities, please visit the careers page.

For more information about St. Paul’s Senior Services and its commitment to serving older adults in San Diego, visit StPaulsSeniors.org.

St. Paul’s Senior Services is a mission-driven San Diego nonprofit and full-service senior care provider, offering Independent Living, Assisted Living, and Skilled Nursing communities, in addition to offering child care and a Program of All-Inclusive Care for the Elderly (PACE). Since opening its doors in 1960, St. Paul’s has served as an innovator in the San Diego community with a reputation for providing award-winning care. For more information on St. Paul’s Senior Services, please visitStPaulsSeniors.org. Press contact: Nicole Antonacci, St. Paul’s Senior Servcies Communications Specialist, 619-239-6900.

Media Contact
Company Name: St. Paul’s Senior Services
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.stpaulseniors.org/

Non-Alcoholic Steatohepatitis Pipeline 2024 | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madr

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the Nonalcoholic Steatohepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Nonalcoholic Steatohepatitis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Nonalcoholic Steatohepatitis Pipeline Outlook

Key Takeaways from the Nonalcoholic Steatohepatitis Pipeline Report

July 2024:- Boston Pharmaceuticals- A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension. This is a randomized, blinded, placebo-controlled study of BOS-580 in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
DelveInsight’s Nonalcoholic Steatohepatitis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Nonalcoholic Steatohepatitis treatment.
The leading Nonalcoholic Steatohepatitis Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others.
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), and others.

Stay ahead with the most recent pipeline outlook for Nonalcoholic Steatohepatitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Nonalcoholic Steatohepatitis Treatment Drugs

Nonalcoholic Steatohepatitis Emerging Drugs Profile

Lanifibranor: Inventiva Pharma

Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH.

MSDC-0602K: Cirius Therapeutics

MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH.

TERN-501: Terns Pharmaceuticals

TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH.

HTD 1801: HighTide Biopharma

The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).

Explore groundbreaking therapies and clinical trials in the Nonalcoholic Steatohepatitis Pipeline. Access DelveInsight’s detailed report now! @ New Nonalcoholic Steatohepatitis Drugs

Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Nonalcoholic Steatohepatitis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Nonalcoholic Steatohepatitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Nonalcoholic Steatohepatitis Market Drivers and Barriers

Scope of the Nonalcoholic Steatohepatitis Pipeline Report

Coverage- Global
Nonalcoholic Steatohepatitis Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others.
Nonalcoholic Steatohepatitis Therapies- AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), and others.
Nonalcoholic Steatohepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Nonalcoholic Steatohepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Nonalcoholic Steatohepatitis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Nonalcoholic Steatohepatitis Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Nonalcoholic Steatohepatitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Lanifibranor: Inventiva Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TERN-501: Terns Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
LY3849891: Eli Lilly and Company
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Drug profiles in the detailed report…..
Inactive Products
Nonalcoholic Steatohepatitis Key Companies
Nonalcoholic Steatohepatitis Key Products
Nonalcoholic Steatohepatitis- Unmet Needs
Nonalcoholic Steatohepatitis- Market Drivers and Barriers
Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
Nonalcoholic Steatohepatitis Analyst Views
Nonalcoholic Steatohepatitis Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Alcoholic Steatohepatitis Pipeline 2024 | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madr

Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets™

“The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.”

Robotic Radiotherapy Market in terms of revenue was estimated to be worth $1.1 billion in 2023 and is poised to reach $1.9 billion by 2028, growing at a CAGR of 11.9% from 2023 to 2028 according to a new report by MarketsandMarkets™.

Robotic Radiotherapy Market in terms of revenue was estimated to be worth $1.1 billion in 2023 and is poised to reach $1.9 billion by 2028, growing at a CAGR of 11.9% from 2023 to 2028 according to a new report by MarketsandMarkets™.

The growth of this market is majorly driven by factors such as the increasing demand for non-invasive treatments, a rise in cancer prevalence, and the widespread adoption of radiotherapy therapy. Additionally, escalating healthcare spending in developing nations, augmented government and private investments, as well as the increasing adoption of radiation therapy, contribute to the market’s growth trajectory during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122256158

The 3D cameras (SGRT) segment is expected to register the highest growth in the forecast period of 2023-2028.

Based on the product, the radiotherapy systems are segmented into radiotherapy systems, software, 3D cameras (SGRT), and others. The radiotherapy systems segment commanded the largest share of the global robotic radiotherapy market in 2022, whereas the 3D cameras (SGRT) segment is projected to grow at the highest CAGR during the forecast period.

SGRT has gained widespread acceptance among cancer facilities worldwide due to its capacity to provide non-invasive, real-time, six-dimensional patient positioning and monitoring throughout radiation therapy treatment. This capability ensures precise treatment administration.

SGRT presents a superior and swifter approach to treating brain tumors compared to invasive technologies or LINAC-based stereotactic radiosurgery. Its increasing adoption is attributed to its effectiveness in radiotherapy for breast cancer when combined with deep inspiration breath hold (DIBH) and voluntary-DIBH (VDIBH), which minimizes radiation-induced damage to the heart. Additionally, the expanding utilization of SGRT in whole-brain radiation therapy (WBRT) and the focus of industry players on introducing innovative 3D cameras and expanding their distribution networks are expected to bolster the growth of this segment in the foreseeable future.

The linear accelerators segment, by technology, is expected to register the market share of the global robotic radiotherapy market in 2023.

Based on technology, the global robotic radiotherapy market is segmented into linear accelerators, stereotactic radiation therapy systems, and particle therapy.

The linear accelerators segment is expected to account for the largest share of the indoor monitors market in 2023, primarily due to the significant advancements in recent years, enhancing their efficiency, precision, and versatility in delivering radiation therapy and ability to administer different types of radiation. Moreover, certain Linacs are equipped with onboard Cone Beam CT (CBCT) technology, facilitating real-time imaging prior to each treatment session. This guarantees accurate targeting, even in the presence of minor alterations in tumor position or patient anatomy. This represents another significant driver for the expansion of the market for fixed indoor monitors.

The lung cancer segment, by application, is expected to register the market share of the global robotic radiotherapy market in 2023.

Based on application, the global robotic radiotherapy market is segmented into prostate cancer, breast cancer, lung cancer, head & neck cancer, colorectal cancer, and other cancers. The lung cancer segment accounted for the largest share of the global robotic radiotherapy market in 2022. This segment is projected to reach USD 0.53 billion in 2028. The growth of the market primarily stems from the increasing occurrences of lung cancer, which may result in a greater caseload. Addressing this trend requires a focus on early detection, enhanced treatment alternatives, and concerted public health initiatives to alleviate the global burden of lung cancer. Additionally, contemporary lifestyles and dietary patterns are bolstering the expansion of this market segment.

Hospitals were the key end-users in the robotic radiotherapy market.

Based on end users, the robotic radiotherapy market is segmented into hospitals and independent radiotherapy centers.

Hospitals commanded the largest share of the global robotic radiotherapy market in 2022. The demand for radiotherapy systems among hospitals is driven by active government initiatives for effective testing, an increased number of research collaborations, and increased installation of robotic radiotherapy stations worldwide.

North America accounted for the largest share of the robotic radiotherapy market by region.

The global robotic radiotherapy market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. North America is the largest regional market for radiotherapy products, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The largest share of North America can be attributed to the rapid adoption of radiotherapy systems, the The presence of a robust healthcare infrastructure, a rising number of cancer patients, substantial government investment to improve access to advanced cancer care through radiotherapy, and favorable reimbursement policies in the region contribute to the situation.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=122256158

Robotic Radiotherapy Market Dynamics:

Drivers:

1. Advancements in radiation therapy technologies

Restraints:

1. Dearth of skilled radiologists/oncologist

Opportunities:

1. Growing Government and Private Investments to Meet the Increasing Demand for Cancer Treatment

Challenge:

1. High cost of automated radiation therapy systems

Key Market Players of Robotic Radiotherapy Industry:

The robotic radiotherapy market was dominated by Siemens Healthineers AG (Germany)-Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuray Incorporated (US), IBA Worldwide (Belgium), and ViewRay, Inc. (US), among others.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
By Designation: C-level–10%, Director-level–14%, and Others–76%
By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, MEA- 3%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122256158

Robotic Radiotherapy Market – Key Benefits of Buying the Report:

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

Analysis of key drivers (growing demand for non-invasive treatments, technological advancements, rising prevalence of cancer, growing use of automated radiation therapy for cancer treatment), restraints (lack of adequate healthcare, high cost of automated radiation therapy systems, complex nature of technology, dearth of skilled radiologist), opportunities (rising healthcare expenditure across developing countries, growing government and private investments, adoption of radiation therapy), and challenges (risk of radiation exposure, competition from alternative treatment modalities) influencing the growth of robotic radiotherapy market
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the robotic radiotherapy market
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the robotic radiotherapy market
Market Development: Comprehensive information on lucrative emerging regions
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the market
Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/robotic-radiotherapy-market-worth-1-9-billion–marketsandmarkets-302116433.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets™

Benign Prostatic Hyperplasia Pipeline 2024 | GemVax & Kael, Antev, Dongkook Pharmaceutical, Chong Kun Dang Pharmaceutical, Resurge Therapeutics Inc., DMK Pharmaceuticals

DelveInsight’s, “Benign Prostatic Hyperplasia Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape. It covers the Benign Prostatic Hyperplasia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Benign Prostatic Hyperplasia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Benign Prostatic Hyperplasia Pipeline Outlook

Key Takeaways from the Benign Prostatic Hyperplasia Pipeline Report

July 2024:- EMS- Phase III, Multicenter, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia. The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia
July 2024:- Vedic Lifesciences Pvt. Ltd.- The present study is a randomized, double-blind, placebo-controlled study. Approximately 125 individuals will be screened, and considering a screening failure rate of 20%, at least 100 will be randomized in a ratio of 1:1 to receive either IP or placebo and will be assigned a unique randomization code. Each group will have not less than 40 completed participants after accounting for a dropout/withdrawal rate of 20%. The intervention duration for all the study participants is 90 days.
DelveInsight’s Benign Prostatic Hyperplasia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Benign Prostatic Hyperplasia treatment.
The leading Benign Prostatic Hyperplasia Companies such as GemVax & Kael, Antev, Dongkook Pharmaceutical, Chong Kun Dang Pharmaceutical, Resurge Therapeutics Inc., DMK Pharmaceuticals, and others
Promising Benign Prostatic Hyperplasia Therapies such as CKD-846, D091, Paclitaxel, alpha blocker and 5-alpha reductase inhibitor, DTT106, Dutasteride-Tamsulosin, and others.

Stay ahead with the most recent pipeline outlook for Benign Prostatic Hyperplasia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Benign Prostatic Hyperplasia Treatment Drugs

Benign Prostatic Hyperplasia Emerging Drugs Profile

DKF-313: Dongkook Pharmaceutical

DKF-313, a combination of dutasteride and tadalafil, is expected to reduce prostate size and improve dysuria symptoms caused by BPH more effectively than single drugs. This combination targets specific antigens overexpressed on cancer cells, allowing for selective targeting. By binding to these target antigens, DKF-313 can deliver the drugs directly to the affected cells, enhancing treatment outcomes. Currently, the drug is in Phase III stage of its clinical trial for the treatment of benign prostatic hyperplasia.

Teverelix trifluoroacetate: Antev

Teverelix trifluoroacetate (Teverelix TFA) is a gonadotrophin-releasing hormone (GnRH) antagonist with a novel formulation. GnRH antagonists rapidly suppress the effects of sex hormones by limiting their production. This is therapeutically valuable for conditions that are controlled by sex hormone secretion, including prostate cancer, benign prostatic hyperplasia, and endometriosis. Recent data suggest that GnRH antagonists may have multiple therapeutic advantages over the traditionally used GnRH agonists, and therefore have the potential to supersede GnRH agonists as the gold-standard treatment. Currently, the drug is in Phase II stage of its clinical trial for the treatment of benign prostatic hyperplasia.

DPI-221: DMK Pharmaceuticals

DPI-221 by DMK Pharmaceuticals is a drug that acts as a highly selective agonist for the δ-opioid receptor, known for producing fewer convulsions compared to other drugs in the same family. This drug is a novel nonpeptide delta receptor agonist that has shown effects such as increased micturition interval in normal rats. Currently, the drug is in Phase I stage of its clinical trial for the treatment of benign prostatic hyperplasia.

Explore groundbreaking therapies and clinical trials in the Benign Prostatic Hyperplasia Pipeline. Access DelveInsight’s detailed report now! @ New Benign Prostatic Hyperplasia Drugs

Benign Prostatic Hyperplasia (BPH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Benign Prostatic Hyperplasia Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Benign Prostatic Hyperplasia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Benign Prostatic Hyperplasia Market Drivers and Barriers

Scope of the Benign Prostatic Hyperplasia Pipeline Report

Coverage- Global
Benign Prostatic Hyperplasia Companies- GemVax & Kael, Antev, Dongkook Pharmaceutical, ChongKun Dang Pharmaceutical, Resurge Therapeutics Inc., DMK Pharmaceuticals, and others
Benign Prostatic Hyperplasia Therapies- CKD-846, D091, Paclitaxel, alpha blocker and 5-alpha reductase inhibitor, DTT106, Dutasteride-Tamsulosin, and others.
Benign Prostatic Hyperplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Benign Prostatic Hyperplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Benign Prostatic Hyperplasia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Benign Prostatic Hyperplasia Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Benign prostatic hyperplasia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Benign prostatic hyperplasia– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
DKF-313: Dongkook Pharmaceutical
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Teverelix trifluoroacetate: Antev
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DPI-221: DMK Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Benign prostatic hyperplasia Key Companies
Benign prostatic hyperplasia Key Products
Benign prostatic hyperplasia- Unmet Needs
Benign prostatic hyperplasia- Market Drivers and Barriers
Benign prostatic hyperplasia- Future Perspectives and Conclusion
Benign prostatic hyperplasia Analyst Views
Benign prostatic hyperplasia Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Benign Prostatic Hyperplasia Pipeline 2024 | GemVax & Kael, Antev, Dongkook Pharmaceutical, Chong Kun Dang Pharmaceutical, Resurge Therapeutics Inc., DMK Pharmaceuticals

Dawna Campbell Announces The Abundant Soul Conference: Empower Colorado Springs’ Holistic Business Community at Unity Spiritual Center

Our goal is to uplift and transform lives by integrating metaphysical wisdom with cutting-edge business strategies,” says Dawna Campbell, co-producer of the conference. “By empowering business owners, we create a ripple effect of abundance that.

The Abundant Soul Metaphysical and Business Conference in Colorado Springs on Sept 9, 2024, offers holistic entrepreneurs, spiritual healers, and business owners insights on combining metaphysical wisdom with business strategies. Led by Dawna Campbell and sponsored by The Los Angeles Tribune, Papas Restaurant and Dazed Creations for a transformative experience at Unity Spiritual Center, featuring soul-centered growth, community development, and practical business expansion techniques.

COLORADO SPRINGS, CO – Aug 5, 2024 – The Abundant Soul Metaphysical and Business Conference, led by renowned transformation expert Dawna Campbell, is positioned to revolutionize the way holistic entrepreneurs approach success. Set for September 9, 2024, at the Unity Spiritual Center of the Rockies, this innovative event promises to be a powerhouse of inspiration for metaphysical and holistic business owners, community leaders, and practitioners.

“Our goal is to uplift and transform lives by integrating metaphysical wisdom with cutting-edge business strategies,” says Dawna Campbell, co-producer of the conference. “By empowering business owners, we create a ripple effect of abundance that nurtures and touches countless lives, supporting a space where personal growth and professional success coexist harmoniously.”

The Abundant Soul Conference redefines business events by offering:

Soul-Centered Business Growth: Discover how to align your spiritual beliefs with profitable business practices, creating a foundation for holistic success.
Community Development: Seize unique opportunities to connect with like-minded individuals committed to collaborative growth.
Effective Strategies: Implement practical approaches to expand trust, credibility, and business reach.
Transformative Experiences: Engage in sessions designed to ignite personal and professional change.

From 10:00 am to 5:30 pm, participants will immerse themselves in transformative sessions with renowned thought leaders, visionary local business experts, and pioneers in the metaphysical and holistic business arena. These experts understand the unique challenges and opportunities within the industry, providing invaluable insights and strategies.

Held at the serene Unity Spiritual Center of the Rockies, located at 1945 Mesa Road, Colorado Springs, CO 80904, this event’s intimate setting ensures personalized attention and cultivates a strong sense of community with deep, meaningful connections among attendees.

Secure your spot now, as tickets are limited and available exclusively online at https://abundant-soul.com. Choose between general admission and premier access tickets, which include premium seating, lunch, and entry to an exclusive private event. Sponsors of the event include The Los Angeles Tribune, Dazed Creations, and Papas Restaurant. Additional sponsorship packages are available for businesses looking to engage with this growth-oriented community.

About The Abundant Soul Conference:

The Abundant Soul Metaphysical and Business Conference is dedicated to creating a vibrant community that embraces abundance in every aspect of life. Its mission is to inspire and transform individuals by merging metaphysical insights with innovative business practices, creating a space where personal growth and professional success coexist harmoniously. At the heart of the conference is the belief that abundance is accessible to everyone. It aims to create a supportive and dynamic environment where attendees can explore new pathways to prosperity and well-being. By uniting like-minded individuals, the conference provides a vibrant platform for sharing knowledge, experiences, and strategies that lead to a more abundant life.

For additional details and media inquiries, please contact:

Jason Antalek, Event Producer

Phone: 1-720-434-8479

4215 Great Place

Colorado Springs, Colorado 80917

Email: jason@latribunebureau.com

Media Contact
Company Name: Healing Heart
Contact Person: Jason Antalek, Event Producer
Email: Send Email
Phone: 1-720-434-8479
Address:4215 Great Place
City: Colorado Springs
State: Colorado 80917
Country: United States
Website: https://abundant-soul.com

Computer Vision in Healthcare Market Worth $11.5 billion | MarketsandMarkets™

“This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a greater share of the market.”

Computer Vision in Healthcare Market in terms of revenue was estimated to be worth $3.9 billion in 2024 and is poised to reach $11.5 billion by 2029, growing at a CAGR of 24.0% from 2024 to 2029 according to a new report by MarketsandMarkets™.

Computer Vision in Healthcare Market in terms of revenue was estimated to be worth $3.9 billion in 2024 and is poised to reach $11.5 billion by 2029, growing at a CAGR of 24.0% from 2024 to 2029 according to a new report by MarketsandMarkets™.

The market’s expansion is fueled by the exponential growth of medical imaging data which necessitates efficient analysis methods, where computer vision techniques excel in automating and enhancing diagnostic processes. Further, the demand for improved patient care and outcomes fuels the adoption of AI-driven solutions, empowering healthcare providers with precise tools for diagnosis, treatment planning, and monitoring. Nevertheless, ensuring the accuracy and reliability of computer vision algorithms remains a significant challenge, especially in complex medical imaging tasks where errors can have critical consequences. Additionally, the regulatory landscape surrounding AI-based medical devices is evolving, requiring stringent validation and approval processes, which can impede the timely deployment of innovative solutions. Thus, restraining the market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231790940

“The largest share in the computer vision in healthcare market, based on type, was attributed to the PC-based computer vision systems segment in 2023.”

The PC-based computer vision systems segment holds the largest market share in the computer vision in healthcare market in 2023. The growth of this segment is propelled by factors such as PCs offering robust computational power, enabling real-time processing of complex algorithms required for tasks like medical image analysis. Also, PCs provide flexibility and scalability, allowing users to customize hardware configurations and software solutions according to specific requirements. This versatility makes them adaptable to various healthcare settings, from small clinics to large hospitals.

“In 2023, the patient activity monitoring/fall prevention segment demonstrated the most significant growth in the computer vision in healthcare market based on hospital management by type.”

The patient activity monitoring/fall prevention segment is expected to experience the highest growth in the computer vision in healthcare market. The key drivers for this growth include the aging population worldwide that has led to an increased focus on elderly care and fall prevention initiatives. Computer vision systems offer non-intrusive and continuous monitoring of patients’ movements, enabling early detection of potential fall risks and timely intervention to prevent accidents. Also, the growing adoption of wearable devices and smart sensors integrated with computer vision technology allows for seamless monitoring of patients’ activities both inside healthcare facilities and at home. This remote monitoring capability enhances patient safety and independence while reducing the burden on caregivers and healthcare resources.

“North America accounted for the largest share of the healthcare simulation market in 2023.”

In 2023, North America held the largest share in the computer vision in healthcare market, with Europe and Asia Pacific following. The significant presence of North America in the global market can be attributed to factors such as region’s strong focus on improving patient outcomes and reducing healthcare costs which incentivizes the integration of computer vision solutions to streamline processes, enhance diagnostics, and optimize treatment pathways.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231790940

Computer Vision in Healthcare Market Dynamics:

Drivers:

The healthcare sector is experiencing a growing need for computer vision systems

Restraints:

The resistance of medical practitioners towards adopting AI-based technologies

Opportunities:

Computer vision solutions for healthcare that are hosted in the cloud

Challenge:

Lack of curated data

Key Market Players of Computer Vision in Healthcare Industry:

The key players functioning in the computer vision in healthcare market include NVIDIA Corporation (US), Intel Corporation (US), Microsoft Corporation (US), Advanced Micro Devices, Inc. (US), Google, Inc. (US), Basler AG (Germany), AiCure (US), iCAD, Inc. (US), Thermo Fisher Scientific Inc. (US), SenseTime (China), KEYENCE CORPORATION (Japan), Assert AI (India), Artisight (US), LookDeep Inc. (US), care.ai (US), CareView Communications (US), VirtuSense (US), Teton (Denmark), viso.ai (Switzerland), NANO-X IMAGING LTD. (Israel), Comofi Medtech Pvt. Ltd. (India), Avidtechvision (India), Roboflow, Inc. (US), Optotune (US) and CureMetrix, Inc. (US).

The break-down of primary participants is as mentioned below:

By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
By Region – North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=231790940

Recent Developments of Computer Vision in Healthcare Industry:

In April 2024, iCAD partnered with RAD-AID to enhance breast cancer detection utilizing the AI technology in underserved regions and low- and middle-income countries (LMICs).
In March 2024, Microsoft and NVIDIA have broadened their longstanding collaboration with robust new integrations that harness cutting-edge NVIDIA generative AI and Omniverse technologies across Microsoft Azure, Azure AI services, Microsoft Fabric, and Microsoft 365.
In February 2022, Advanced Micro Devices acquired Xilinx. This acquisition established the forefront leader in high-performance and adaptive computing, with a significantly expanded scale and the most formidable portfolio of leadership computing, graphics, and adaptive SoC products in the industry.

Computer Vision in Healthcare Market – Key Benefits of Buying the Report:

This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/computer-vision-in-healthcare-market-worth-11-5-billion–marketsandmarkets-302135475.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Computer Vision in Healthcare Market Worth $11.5 billion | MarketsandMarkets™

Facioscapulohumeral Muscular Dystrophy Pipeline 2024 | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc.

DelveInsight’s, “Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this space.

Discover the latest drugs and treatment options in the Facioscapulohumeral Muscular Dystrophy Pipeline. Dive into DelveInsight’s comprehensive report today! @ Facioscapulohumeral Muscular Dystrophy Pipeline Outlook

Key Takeaways from the Facioscapulohumeral Muscular Dystrophy Pipeline Report

July 2024:- Hoffmann-La Roche– A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy.
DelveInsight’s Facioscapulohumeral Muscular Dystrophy pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Facioscapulohumeral Muscular Dystrophy treatment.
The leading Facioscapulohumeral Muscular Dystrophy Companies such as Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc., and others.
Promising Facioscapulohumeral Muscular Dystrophy Therapies such as Losmapimod, RO7204239, AOC 1020, and others.

Stay ahead with the most recent pipeline outlook for Facioscapulohumeral Muscular Dystrophy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Facioscapulohumeral Muscular Dystrophy Treatment Drugs

Facioscapulohumeral Muscular Dystrophy Emerging Drugs Profile

Losmapimod: Fulcrum Therapeutics

Losmapimod is an investigational, selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum’s discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Results reported from the ReDUX4 trial demonstrated slowed disease progression and improved function, including positive impacts on upper extremity strength, supporting losmapimod’s potential to be a transformative therapy for the treatment of FSHD. Although losmapimod had never previously been explored in muscular dystrophies, it had been evaluated in more than 3,600 subjects in clinical trials across multiple other indications, with no safety signals attributed to losmapimod.

DYNE-301: Dyne Therapeutics

DYNE-301 is a DUX4L1 protein expression stimulant, which consists of company’s proprietary Fab conjugated with our linker to an ASO that is designed to address the genetic basis of FSHD by reducing DUX4 expression in muscle tissue. Proof-of-concept data showing that DYNE-301 reduced expression of key DUX4 biomarkers in FSHD patient myotubes, a type of muscle cell. Currently the product is in preclinical stage of development for the disease.

Explore groundbreaking therapies and clinical trials in the Facioscapulohumeral Muscular Dystrophy Pipeline. Access DelveInsight’s detailed report now! @ New Facioscapulohumeral Muscular Dystrophy Drugs

Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Facioscapulohumeral Muscular Dystrophy Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Unveil the future of Facioscapulohumeral Muscular Dystrophy Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Facioscapulohumeral Muscular Dystrophy Market Drivers and Barriers

Scope of the Facioscapulohumeral Muscular Dystrophy Pipeline Report

Coverage- Global
Facioscapulohumeral Muscular Dystrophy Companies- Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc., and others.
Facioscapulohumeral Muscular Dystrophy Therapies- Losmapimod, RO7204239, AOC 1020, and others.
Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Facioscapulohumeral Muscular Dystrophy Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Facioscapulohumeral Muscular Dystrophy Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Facioscapulohumeral Muscular Dystrophy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Facioscapulohumeral Muscular Dystrophy– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Losmapimod: Fulcrum Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
DYNE-301: Dyne Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Facioscapulohumeral Muscular Dystrophy Key Companies
Facioscapulohumeral Muscular Dystrophy Key Products
Facioscapulohumeral Muscular Dystrophy- Unmet Needs
Facioscapulohumeral Muscular Dystrophy- Market Drivers and Barriers
Facioscapulohumeral Muscular Dystrophy- Future Perspectives and Conclusion
Facioscapulohumeral Muscular Dystrophy Analyst Views
Facioscapulohumeral Muscular Dystrophy Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Facioscapulohumeral Muscular Dystrophy Pipeline 2024 | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc.

Clinical Communication & Collaboration Market Worth $4.8 billion | MarketsandMarkets™

“North America accounted for the largest share of the Clinical Communication and Collaboration market. This region’s dominance is due to highly developed healthcare infrastructure characterized by advanced technology adoption, robust regulatory frameworks, and a strong emphasis on patient-centric care delivery.”

Clinical Communication & Collaboration Market in terms of revenue was estimated to be worth $2.6 billion in 2024 and is poised to reach $4.8 billion by 2029, growing at a CAGR of 13.2% from 2024 to 2029 according to a new report by MarketsandMarkets™.

Clinical Communication & Collaboration Market in terms of revenue was estimated to be worth $2.6 billion in 2024 and is poised to reach $4.8 billion by 2029, growing at a CAGR of 13.2% from 2024 to 2029 according to a new report by MarketsandMarkets™.

The growth in the clinical communication and collaboration market is driven by high prevalence of chronic diseases, rising prominence of big data and mHelath tools, and stringent regulatory requirements and industry standards. Moreover, transition towards value-based care and population health management further increases the significance of clinical communication and collaboration solutions. Thus, the the growing emphasis on interoperability and data exchange within healthcare ecosystems is expected to drive the integration of clinical communication and collaboration market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=118830286

Software segment accounted for the largest share of the global Clinical Communication and Collaboration market in 2023.

On the basis component, the Clinical Communication and Collaboration market is segmented into hardware, software and services segment. The software segment accounted for the largest share of the component segment in 2023. The software segment comprises of clinical alerting & notification, physician & nurse scheduling systems, telehealth platform, collaborative care platforms. The clinical alerting & notification segment held the largest market share in the software segment. These systems plays a pivotal role in enhancing patient safety, as it reduces response times, and improves clinical decision-making. Moreover, the increasing focus on care coordination and continuity across healthcare settings has propelled the demand for robust clinical alerting and notification solutions. Owing to the many benefits of the software solutions, several healthcare providers are increasingly adopting these solutions for smooth workflows and enhanced quality care.

By application, physician communication segment accounted for the largest market share in 2023.

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication. The physician communication segment held the largest market in 2023 due to its pivotal role in facilitating effective care delivery, and enhancing care coordination. Moreover, the unique communication needs of physicians, including the requirement for secure and confidential communication channels, further highlights the importance of dedicated physician communication solutions within the clinical communication and collaboration market. These solutions offer encrypted messaging, secure voice and video calling, and other advanced features tailored to the specific requirements of healthcare providers, enabling them to communicate effectively while adhering to stringent privacy and security regulations.

Hospitals & clinics are largest end users of the Clinical Communication and Collaboration market

Based on end users, the Clinical Communication and Collaboration market is segmented into hospitals & clinics, ambulatory surgical centers, long-term care facilities, nursing centers and other end-users which includes maternity care centers & fertility centers, and trauma and emergency care centers. The hospitals & clinics held the largest share among the end-users in 2023. From emergency departments and operating rooms to inpatient units and outpatient clinics, healthcare providers in hospitals and clinics rely heavily on effective communication channels to coordinate care plans, consult with colleagues, and ensure continuity of care for patients. As healthcare organizations continue to prioritize communication solutions that enhances care coordination, streamlines workflows, and support remote care delivery, hospitals and clinics are poised to remain key drivers of innovation and growth in the clinical communication and collaboration market.

North America dominates the global Clinical Communication and Collaboration market.

The Clinical Communication and Collaboration market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2023, North America accounted for the largest share of the Clinical Communication and Collaboration market. This region’s dominance is due to highly developed healthcare infrastructure characterized by advanced technology adoption, robust regulatory frameworks, and a strong emphasis on patient-centric care delivery. Moreover, the presence of key market players such as Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US) among others are a key factor contributing to the growth of the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=118830286

Clinical Communication & Collaboration Market Dynamics:

Drivers:

Advantages of clinical communication solutions in enhancing patient care and safety

Restraints:

High investments required to build IT infrastructure

Opportunities:

Growing opportunities in emerging markets

Challenge:

Data security issues

Key Market Players of Clinical Communication & Collaboration Industry:

Prominent players in the Clinical Communication and Collaboration market include Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US), Baxter International (Hillrom) (US), symplr (US), NEC Corporation (Japan), Spok Inc. (US), Vocera Communications (Stryker) (US), Ascom Holding AG (Switzerland), Everbridge (US), Hidden Brains InfoTech. (India), Imprivata, Inc. (US), CommuniCare Technology, Inc. d/b/a Pulsara (US), Mobile Heartbeat (C-HCA, Inc.) (US), OnPage. (US), HARRIS ONPOINT (US), Jive Software, LLC (US), TigerConnect (US), JCT Healthcare Pty Ltd. (Australia), Amplion (US), AndorHealth (US), PerfectServe, Inc. (US), QliqSOFT, Inc. (US), and Connexall, GlobeStar Systems Inc. (Canada).

Breakdown of supply-side primary interviews, by company type, designation, and region:

By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
By Designation: C-level (35%), Director-level (45%), and Others (20%)
By Region: North America (55%), Europe (20%), Asia Pacific (15%), Latin America (5%) and Middle East Africa (5%)

Recent Developments of Clinical Communication & Collaboration Industry:

In September 2023, Microsoft Corporation (US) collaborated with Mercy (US) to enable clinicians to revolutionize patient care through the use of generative AI.
In August 2023, TeleVox (US) partnered with Oracle (US) to enhance its patient engagement solutions, leveraging OCI’s platform for improved communication in healthcare. As part of the Oracle PartnerNetwork (OPN), TeleVox on OCI delivers advanced capabilities for healthcare practices.
In April 2023, Mobile Heartbeat (US) partnered with Akkadian Labs, LLC. (US) a leading developer of unified communications (UC) provisioning automation solutions. With this partnership, Mobile Heartbeat and Akkadian Labs aim to empower healthcare organizations with enhanced communication and collaboration capabilities, ultimately improving patient care outcomes.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=118830286

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/clinical-communication–collaboration-market-worth-4-8-billion–marketsandmarkets-302110826.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Clinical Communication & Collaboration Market Worth $4.8 billion | MarketsandMarkets™

Sell N Buy Wireless: Safe and Easy Way to Sell Devices for Cash in Warren, MI

Residents of Warren, MI, now have a safe and easy way to sell their phones, laptops, and tablets. Sell N Buy Wireless, a new cell phone store located at 28051 John R Rd, Madison Heights, MI 48071, offers a secure process that puts cash in sellers’ pockets without the hassle of meeting random strangers.

Sell N Buy Wireless makes the selling process straightforward and secure. All sellers need to do is reset and wipe their devices and bring a valid ID. The store ensures a fast and efficient sale, providing immediate cash in hand. This eliminates the uncertainty and potential risks associated with online selling platforms.

The store’s mission is to create a safe environment where everyone can sell their devices with confidence. By offering a reliable and secure alternative to meeting unknown buyers, Sell N Buy Wireless is revolutionizing the way Warren, MI, residents sell their electronics.

If you’re looking to sell your phone, laptop, or tablet, stop by Sell N Buy Wireless. Experience a safe, easy, and quick transaction, and walk out with cash in your pocket. Visit us today and see why Sell N Buy Wireless is the best choice for selling your devices in Warren, MI.

For directions, click here. https://maps.app.goo.gl/XAcYr6N2hLdQVzdaA

To learn more about selling, click here. https://www.sellnbuywireless.com/sell/

Visit our website: Sell N Buy Wireless. https://www.sellnbuywireless.com/

Media Contact
Company Name: Sell N Buy Wireless
Contact Person: Abe Ismael
Email: Send Email
Phone: 248-990-1472
Address:28051 John R Rd
City: Madison Heights
State: MI 48071
Country: United States
Website: https://www.sellnbuywireless.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sell N Buy Wireless: Safe and Easy Way to Sell Devices for Cash in Warren, MI

Revolutionizing Auto Parts Shopping: 7zap.com Sets a New Standard in Efficiency

7zap.com is a revolutionary platform transforming the auto parts industry. Catering to skilled mechanics, car enthusiasts, and vehicle owners alike, 7zap.com aims to simplify the often cumbersome task of sourcing authentic and correctly fitting auto parts. Whether you’re Mike, a professional mechanic, or Sarah, a passionate DIY car enthusiast, 7zap.com addresses the diverse needs of its users with a user-friendly and precise approach.

Key features

7zap.com offers a comprehensive and reliable solution for sourcing auto parts. Key features include:

1. Extensive Auto Parts Catalog: An impressive database covering a wide range of vehicle makes and models. Each listing is detailed with images, specifications, and part numbers.

2. VIN-Based Search Tool: This tool provides a curated and accurate list of parts tailored specifically to a vehicle by using its unique Vehicle Identification Number (VIN).

3. Specialized Manufacturer Catalogs: In addition to a general catalog, the platform offers specific catalogs for brands like Audi, easing the process of finding brand-specific parts.

4. User-Friendly Interface: Designed with the user in mind, featuring easily understandable categories and robust search functionalities.

The demand for a reliable auto parts platform has never been more critical, considering the ever-evolving automotive landscape. From older vehicles to the latest models, the need for precision and reliability in sourcing parts has prompted users like Mike and Sarah to turn to 7zap.com for their automotive needs.

Where to access

7zap.com operates entirely online, making it accessible to users globally. Whether you’re working from a bustling mechanic workshop in Europe or managing a DIY car project from your home garage, the platform is designed to accommodate users from all corners of the world. The convenience of an online platform ensures that you can source parts from anywhere and at any time.

Why You Need 7zap.com

The traditional methods of sourcing auto parts often lead to confusion, mistakes, and costly errors, disrupting plans and jeopardizing vehicle performance and safety. Here’s why 7zap.com stands out as a game-changer in the industry:

1. Accuracy: Ensures the right part every time with the VIN-based search tool, reducing the risk of incorrect part orders.

2. Efficiency: Saves time by providing detailed part information and tailored search results.

3. Quality: Offers an extensive database of OEM parts, guaranteeing top-notch quality and a perfect fit.

4. User Experience: Features a user-friendly interface that simplifies navigation and enhances the shopping experience.

Real-World Applications

– Professional Mechanics: Mike, running a busy workshop, relies on 7zap.com to quickly source specific transmission components for an Audi A6. This efficiency ensures his client’s vehicle is back on the road swiftly and safely.

– DIY Enthusiasts: Sarah, passionate about her Audi Q5, uses the VIN-based search tool on 7zap.com to accurately identify and order brake pads, avoiding the hassle of returns and exchanges.

Advantages of OEM Parts

7zap.com’s commitment to OEM parts brings several benefits:

1. Guaranteed Quality: OEM parts meet the high standards set by the vehicle’s original manufacturer.

2. Perfect Fit: Designed specifically for your vehicle, reducing operational issues.

3. Preserved Warranty: Helps maintain your vehicle’s warranty.

4. Enhanced Safety: High quality and a perfect fit contribute to the overall safety of your vehicle.

User Testimonials

– James R., Professional Mechanic: “7zap.com is a lifesaver. The platform’s detailed auto parts catalog and the VIN-based search make sourcing parts a breeze. The quality and specificity of OEM parts ensure that I can deliver the best service to my clients.”

– Ellie M., Car Enthusiast: “Finding the right parts for my Audi used to be a nightmare. Since I started using 7zap.com, I’ve had nothing but positive experiences. The OEM parts fit perfectly, and the website is incredibly user-friendly.”

– Tom S., DIYer: “I was initially skeptical about buying car parts online, but 7zap.com changed that. The VIN-based search feature ensures I get the exact parts I need, and the Audi catalog is fantastic. I highly recommend it.”

Conclusion

7zap.com is a premier solution for sourcing auto parts in an industry where accuracy, reliability, and efficiency are essential. Its extensive auto parts catalog, unique VIN-based search feature, and specialized manufacturer catalogs make it an indispensable tool for anyone involved in automotive repair and maintenance. Whether you’re a seasoned mechanic, a DIY enthusiast, or an Audi aficionado, 7zap.com offers a seamless and reliable parts shopping experience.

Don’t let the complexities of auto parts shopping bog you down. Visit 7zap.com today and experience a world of precision, quality, and convenience. For all the Audi owners, explore the dedicated Audi catalog to find the best parts tailored to your vehicle’s needs.

With 7zap.com, you’re not just purchasing parts; you’re ensuring the longevity and optimal performance of your vehicle. Start your journey today and witness the transformative difference of a truly innovative auto parts platform.

Media Contact
Company Name: 7zap.com
Contact Person: Viktor Stupko
Email: Send Email
City: Berlin
Country: Germany
Website: 7zap.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Revolutionizing Auto Parts Shopping: 7zap.com Sets a New Standard in Efficiency